Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 May;25(5):555–560. doi: 10.1111/j.1365-2125.1988.tb03345.x

Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: a study in normal healthy volunteers.

S Mousdale 1, P A Clyburn 1, A M Mackie 1, N D Groves 1, M Rosen 1
PMCID: PMC1386428  PMID: 3408636

Abstract

1. We compared the effects of dopexamine, dopamine and dobutamine on the heart rate, blood pressure and renal blood flow of six healthy volunteers in an open triple crossover trial. 2. The results suggest that at the dose ranges investigated dopamine was the most effective agent for increasing renal blood flow.

Full text

PDF
555

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown R. A., Farmer J. B., Hall J. C., Humphries R. G., O'Connor S. E., Smith G. W. The effects of dopexamine on the cardiovascular system of the dog. Br J Pharmacol. 1985 Jul;85(3):609–619. doi: 10.1111/j.1476-5381.1985.tb10555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cohn J. N., Franciosa J. A. Vasodilator therapy of cardiac failure (second of two parts). N Engl J Med. 1977 Aug 4;297(5):254–258. doi: 10.1056/NEJM197708042970506. [DOI] [PubMed] [Google Scholar]
  3. Dawson J. R., Thompson D. S., Signy M., Juul S. M., Turnbull P., Jenkins B. S., Webb-Peploe M. M. Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. Br Heart J. 1985 Sep;54(3):313–320. doi: 10.1136/hrt.54.3.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jaski B. E., Wijns W., Foulds R., Serruys P. W. The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist. Br J Clin Pharmacol. 1986 Apr;21(4):393–400. doi: 10.1111/j.1365-2125.1986.tb05213.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Leach K. G., Slowey H. F., Rosen M., Asscher A. W. Serial measurement of renal plasma flow. Eur J Nucl Med. 1985;11(1):33–35. doi: 10.1007/BF00440958. [DOI] [PubMed] [Google Scholar]
  6. Pritchard W. H., Eckstein R. W., MacIntyre W. J., Dabaj E. Correlation of renal blood flow determined by the single injection of Hippuran-I 131 with direct measurements of flow. Am Heart J. 1965 Dec;70(6):789–796. doi: 10.1016/0002-8703(65)90334-0. [DOI] [PubMed] [Google Scholar]
  7. Svensson G., Sjögren A., Erhardt L. Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure. Eur Heart J. 1986 Aug;7(8):697–703. doi: 10.1093/oxfordjournals.eurheartj.a062125. [DOI] [PubMed] [Google Scholar]
  8. Tauxe W. N., Dubovsky E. V., Kidd T. E. Comparison of measurement of effective renal plasma flow by single plasma sample and plasma disappearance slope/volume methods. Eur J Nucl Med. 1984;9(10):443–445. doi: 10.1007/BF00563166. [DOI] [PubMed] [Google Scholar]
  9. Tauxe W. N., Maher F. T., Taylor W. F. Effective renal plasma flow: estimation from theoretical volumes of distribution of intravenously injected 131-I orthoiodohippurate. Mayo Clin Proc. 1971 Aug;46(8):524–531. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES